[{"address1": "5505 Morehouse Drive", "address2": "Suite 100", "city": "San Diego", "state": "CA", "zip": "92121", "country": "United States", "phone": "858 267 4467", "website": "https://www.artivabio.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Artiva Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing natural killer (NK) cell-based therapies for patients suffering from autoimmune diseases and cancers. The company's lead product candidate includes AlloNK, an off-the-shelf NK cell therapy for patients with autoimmune diseases and cancers, such as rheumatoid arthritis, systemic lupus erythematosus, lupus nephritis, rheumatoid arthritis, pemphigus vulgaris, the anti-neutrophil cytoplasmic antibody -associated vasculitis subtypes granulomatosis with polyangiitis/microscopic polyangiitis, and B-cell-non-Hodgkin lymphoma. It also develops AB-201, an allogeneic anti- human epidermal growth factor receptor 2 targeting chimeric antigen receptor (CAR)-NK cell product candidate for the treatment of various solid tumors, such as breast, gastric and esophageal, and bladder cancers; and AB-205, an allogeneic anti-CD5 CAR-NK cell product candidate for the treatment of hematological malignancies. Artiva Biotherapeutics, Inc. was incorporated in 2019 and is headquartered in San Diego, California.", "fullTimeEmployees": 89, "companyOfficers": [{"maxAge": 1, "name": "Dr. Fred  Aslan M.D.", "age": 48, "title": "President, CEO & Director", "yearBorn": 1976, "fiscalYear": 2023, "totalPay": 917304, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Peter  Flynn Ph.D.", "age": 50, "title": "Co-Founder & Strategic Advisor", "yearBorn": 1974, "fiscalYear": 2023, "totalPay": 499368, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Jennifer Kinsbruner Bush Esq., J.D.", "age": 49, "title": "Executive VP, COO, Chief Legal Officer, Corporate Secretary & Compliance Officer", "yearBorn": 1975, "fiscalYear": 2023, "totalPay": 630312, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Christopher P. Horan", "age": 56, "title": "Chief Technical Operations Officer", "yearBorn": 1968, "fiscalYear": 2023, "totalPay": 612234, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Neha  Krishnamohan", "age": 36, "title": "CFO & Executive VP of Corporate Development", "yearBorn": 1988, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}], "compensationAsOfEpochDate": 1703980800, "executiveTeam": [], "maxAge": 86400, "priceHint": 4, "previousClose": 2.3, "open": 2.26, "dayLow": 2.15, "dayHigh": 2.27, "regularMarketPreviousClose": 2.3, "regularMarketOpen": 2.26, "regularMarketDayLow": 2.15, "regularMarketDayHigh": 2.27, "payoutRatio": 0.0, "forwardPE": -0.64927536, "volume": 288987, "regularMarketVolume": 288987, "averageVolume": 282114, "averageVolume10days": 1210760, "averageDailyVolume10Day": 1210760, "bid": 2.22, "ask": 2.28, "bidSize": 1, "askSize": 1, "marketCap": 54573344, "fiftyTwoWeekLow": 1.78, "fiftyTwoWeekHigh": 17.31, "priceToSalesTrailing12Months": 217.42368, "fiftyDayAverage": 3.8084, "twoHundredDayAverage": 9.1191225, "trailingAnnualDividendRate": 0.0, "trailingAnnualDividendYield": 0.0, "currency": "USD", "tradeable": false, "enterpriseValue": -116500616, "profitMargins": 0.0, "floatShares": 4396812, "sharesOutstanding": 24363100, "sharesShort": 1081185, "sharesShortPriorMonth": 1124353, "sharesShortPreviousMonthDate": 1740700800, "dateShortInterest": 1743379200, "sharesPercentSharesOut": 0.0444, "heldPercentInsiders": 0.22633, "heldPercentInstitutions": 0.90841, "shortRatio": 7.85, "shortPercentOfFloat": 0.0446, "impliedSharesOutstanding": 24363100, "bookValue": 7.683, "priceToBook": 0.29155278, "lastFiscalYearEnd": 1735603200, "nextFiscalYearEnd": 1767139200, "mostRecentQuarter": 1735603200, "netIncomeToCommon": -65373000, "trailingEps": -5.81, "forwardEps": -3.45, "enterpriseToRevenue": -464.146, "enterpriseToEbitda": 1.796, "52WeekChange": -0.81333333, "SandP52WeekChange": 0.05430484, "quoteType": "EQUITY", "currentPrice": 2.24, "targetHighPrice": 23.0, "targetLowPrice": 18.0, "targetMeanPrice": 20.4, "targetMedianPrice": 20.0, "recommendationKey": "none", "numberOfAnalystOpinions": 5, "totalCash": 185428000, "totalCashPerShare": 7.611, "ebitda": -64851000, "totalDebt": 14354000, "quickRatio": 15.219, "currentRatio": 15.395, "totalRevenue": 251000, "debtToEquity": 7.691, "revenuePerShare": 0.022, "returnOnAssets": -0.26725, "returnOnEquity": -0.54243, "grossProfits": 251000, "freeCashflow": -33753248, "operatingCashflow": -55032000, "revenueGrowth": -1.0, "grossMargins": 1.0, "ebitdaMargins": 0.0, "operatingMargins": -268.0558, "financialCurrency": "USD", "symbol": "ARTV", "language": "en-US", "region": "US", "typeDisp": "Equity", "quoteSourceName": "Nasdaq Real Time Price", "triggerable": true, "customPriceAlertConfidence": "HIGH", "corporateActions": [], "postMarketTime": 1744933846, "regularMarketTime": 1744920002, "exchange": "NGM", "messageBoardId": "finmb_672643147", "exchangeTimezoneName": "America/New_York", "exchangeTimezoneShortName": "EDT", "gmtOffSetMilliseconds": -14400000, "market": "us_market", "esgPopulated": false, "regularMarketChangePercent": -2.6086931, "regularMarketPrice": 2.24, "shortName": "Artiva Biotherapeutics, Inc.", "longName": "Artiva Biotherapeutics, Inc.", "cryptoTradeable": false, "hasPrePostMarketData": true, "fiftyTwoWeekLowChange": 0.46000004, "fiftyTwoWeekLowChangePercent": 0.258427, "fiftyTwoWeekRange": "1.78 - 17.31", "fiftyTwoWeekHighChange": -15.07, "fiftyTwoWeekHighChangePercent": -0.87059504, "fiftyTwoWeekChangePercent": -81.333336, "earningsTimestamp": 1742846700, "earningsTimestampStart": 1742846700, "earningsTimestampEnd": 1742846700, "isEarningsDateEstimate": false, "epsTrailingTwelveMonths": -5.81, "epsForward": -3.45, "epsCurrentYear": -2.54, "priceEpsCurrentYear": -0.88188976, "fiftyDayAverageChange": -1.5683999, "fiftyDayAverageChangePercent": -0.41182646, "twoHundredDayAverageChange": -6.8791227, "twoHundredDayAverageChangePercent": -0.75436234, "sourceInterval": 15, "exchangeDataDelayedBy": 0, "ipoExpectedDate": "2024-07-19", "firstTradeDateMilliseconds": 1721395800000, "postMarketChangePercent": 0.0044597, "postMarketPrice": 2.2401, "postMarketChange": 9.98974e-05, "regularMarketChange": -0.059999943, "regularMarketDayRange": "2.15 - 2.27", "fullExchangeName": "NasdaqGM", "averageDailyVolume3Month": 282114, "marketState": "CLOSED", "displayName": "Artiva Biotherapeutics", "trailingPegRatio": null, "__fetch_time": "2025-04-19"}]